387.54 0.00 (0.00%)
After hours: 4:05PM EST
|Bid||387.20 x 200|
|Ask||439.00 x 300|
|Day's Range||384.50 - 388.39|
|52 Week Range||340.09 - 543.55|
|PE Ratio (TTM)||38.88|
|Earnings Date||Jan 31, 2018 - Feb 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||474.09|
This could indicate that investors who seek to profit from falling equity prices are not currently targeting REGN. Over the last one-month, outflows of investor capital in ETFs holding REGN totaled $1.27 billion.
TARRYTOWN, N.Y. , Nov. 15, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast a management presentation at the 29 th Annual Piper Jaffray Healthcare Conference at 4:00 p.m. ...
In 3Q17, Novartis's (NVS) Lucentis generated revenues of ~$481 million, which was ~5% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).
The pan-European STOXX 600 (.STOXX) was 0.7 percent lower at its close, with almost every sector ending in negative territory. France's EDF was the biggest faller on the day, dropping more than 10 percent after lowering its 2018 earnings and cash flow forecasts. Exane BNP Paribas affirmed its underperform rating on EDF.
Novartis's (NOVN.S) bid to move in on Bayer's (BAYGn.DE) and Regeneron's (REGN.O) eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea. Active disease was observed in 23.5 percent of RTH258 patients versus 33.5 percent of Eylea patients at 16 weeks, Novartis said, of its investigational treatment for wet age-related macular degeneration (AMD), where abnormal, leaky blood vessels can cause blindness. A second, similar study found active disease in 21.9 percent of RTH258 patients versus 31.4 percent of those on Eylea for the condition affecting 20-25 million people worldwide.
Biotech stocks require a good deal of faith from investors. And with third quarter earnings season coming to an end, that faith has been shaken as a string of companies, including Amgen (AMGN), Biogen ...
While focus remained on Regeneron's (REGN) Q3 earnings, Dicerna was also in the news related to its collaboration agreement with Boehringer Ingelheim.
Regeneron Pharmaceuticals is about to release a television ad campaign for one of its newest products, eczema medication Dupixent. The drug developer's total sales grew 23 percent to $1.5 billion over the past three months, propelled by sales of its Eylea medication that treats patients with macular degeneration, a leading cause of adult blindness. Eylea sales for the third quarter increased by nearly $100 million to $953.3 million compared to the same period in 2016.
With an ROE of 24.06%, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) outpaced its own industry which delivered a less exciting 16.08% over the past year. Superficially, this looks great since we knowRead More...
Regeneron Pharmaceuticals’s (REGN) third quarter earnings report is a bright spot in what has been a dim month for the iShares Nasdaq Biotechnology ETF (IBB). The stock popped in morning market action, lifted 2.7% to $415.42 a share by estimate-beating results. On the bottom line, Leerink’s Geoffrey Porges says there was a “surprise in operating efficiency.” Up 2.4% today to $414.19 a share, Regeneron’s stock was on fire for much of 2017, rising to a 52-week high $543.55 a share in late June on the success of the Dupixent launch.
U.S. stocks stalled in late morning trading on Wednesday as weak oil prices weighed on energy stocks and doubts over a Republican tax plan and the broader outlook for U.S. growth hurt banks. Investors ...
Wall Street was trading slightly lower on Wednesday as bank stocks came under pressure from a near-flat Treasury yield curve and investors remained focused on the debate among lawmakers over the tax bill. Goldman Sachs was the biggest drag on the Dow while Bank of America weighed on the S&P. The S&P financial sector led the decliners, falling 0.7 percent. Senate Republican leaders are considering a one-year delay in the implementation of a major corporate tax cut to comply with Senate rules, The Washington Post reported on Tuesday, citing unidentified sources.
Wall Street looked set to open flat on Wednesday, a day after the Dow closed at a record high for the fourth straight day, as investors keep a close tab on the debate among lawmakers on the tax bill. Shares of Snapchat operator Snap fell 11.2 percent in premarket trading after China's Tencent took a 12 percent stake. As well as slashing the corporate rate to 20 percent from 35 percent, the bill would eliminate many tax breaks and is expected to face opposition from interest groups.
Jim Cramer talked bitcoin, allergies, millennials and more to see how executives are shaping their businesses to meet the needs of modern consumers.
Jim Cramer caught up with Regeneron Pharmaceuticals founder, Chairman and CEO Dr. Leonard Schleifer, who pushed back against his company's rival Novartis.
Nov.08 -- Regeneron President and Chief Scientific Officer George D. Yancopoulos talks with Bloomberg's Joe Weisenthal at The Year Ahead Summit at Bloomberg headquarters in New York about the latest breakthroughs in health-care technology.